Women's health: 8 weeks on CJC-1295/Ipamorelin
I wanted to share my progress after 8 weeks on a CJC-1295/Ipamorelin protocol (100mcg/100mcg nightly). My primary goal was body recomposition and better sleep quality. The results have been subtle but consistent. My body fat percentage dropped from 26% to 23%, and my sleep tracking shows I’m spending about 45 minutes more in deep sleep per night. I haven't experienced any major side effects, just some mild water retention in the first two weeks which cleared up once I increased my water intake. My doctor is happy with my bloodwork, specifically my IGF-1 levels which are now in the optimal range for my age. For the ladies here, have you found that this stack affects your cycle at all? I’ve noticed mine is a few days early, but that could just be stress. Overall, feeling much more energized and recovered after my lifting sessions.
It is great to hear about your consistent progress! A 3% body fat drop in eight weeks while improving sleep architecture is a strong result. The mechanism behind your experience is likely the pulsatile release of Growth Hormone (GH) stimulated by the Ipamorelin, which acts as a selective ghrelin receptor agonist, combined with the CJC-1295's ability to extend the duration of those GH pulses by antagonizing somatostatin. Increased deep sleep is a classic indicator that the GH axis is being optimized, as slow-wave sleep is heavily linked to endogenous GH secretion cycles. Regarding your initial water retention, that is quite common as the body adjusts to sudden shifts in fluid regulation often associated with the upregulation of IGF-1. Since you have hit this milestone, many users find that keeping an eye on fasting glucose is a smart move, as increased IGF-1 can occasionally influence insulin sensitivity. Staying well-hydrated, as you discovered, remains the best tool for mitigating those minor side effects. Keep tracking your metrics, as the long-term benefits for recovery and body composition often become even more apparent after the 12-week mark.